- Follicular Lymphoma
- B-Cell Lymphoma
- Others
Non-Hodgkin’s lymphoma is a cancer that originates in lymphatic system. Non-Hodgkin’s lymphoma tumors develop from lymphocytes. It is more common than Hodgkin’s lymphoma. Several type of non-Hodgkin lymphomas, among them follicular lymphoma and diffuse B-Cell lymphoma are most common subtypes. Symptoms may include painless swelling of limp nodes in neck, armpits, or groin, abdominal pain, chest pain, and others. Disease will be diagnosed through imaging tests, lymph node tests, and bone marrow tests.
Non-Hodgkin’s lymphoma is generally treated by chemotherapy, radiation therapy, bone marrow replacement, and drug therapies. Drug therapies include monoclonal antibodies and other immune system agents. Furthermore radiotherapy drugs are used to act on cancer cells.
Key Developments:
- In June 2017, Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and ADCETRIS (BrentuximabVedotin) in Pivotal Phase 3 Clinical Trial in Relapsed Hodgkin Lymphoma.
- In February 2017, Kite Pharma announced Positive Topline Primary Results of AxicabtageneCiloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma.
Non-Hodgkin’s Lymphoma Disease Pipeline Drugs Assessment Dynamics
Non-Hodgkin’s Lymphoma Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Non-Hodgkin’s Lymphoma treatment along with targets for various drug candidate. The report provides plethora of information on trail phases, companies involved in the Non-Hodgkin’s Lymphoma disease pipeline drugs development. This report studies the dynamics of the Non-Hodgkin’s Lymphoma Disease Pipeline Drugs i.e. drivers, challenges, and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Non-Hodgkin’s Lymphoma disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Non Hodgkins Lymphoma Disease Pipeline Drugs Assessment Segmentation
By Type
By Route of Administration
- Oral
- Parenteral
- Others
Frequently Asked Questions
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
| 1. Executive Summary |
| 2. Global Non Hodgkins Lymphoma Disease Pipeline Drugs Assessment Market Introduction |
| 2.1.Global Non Hodgkins Lymphoma Disease Pipeline Drugs Assessment Market - Taxonomy |
| 2.2.Global Non Hodgkins Lymphoma Disease Pipeline Drugs Assessment Market - Definitions |
| 2.2.1.Type |
| 2.2.2.Route of Administration |
| 3. Global Non Hodgkins Lymphoma Disease Pipeline Drugs Assessment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Non Hodgkins Lymphoma Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Non Hodgkins Lymphoma Disease Pipeline Drugs Assessment Market By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Follicular Lymphoma |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. B-Cell Lymphoma |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Non Hodgkins Lymphoma Disease Pipeline Drugs Assessment Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Parenteral |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Competition Landscape |
| 7.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 7.2.1.Gilead Sciences, Inc. (U.S.) |
| 7.2.2.CTI BioPharma (U.S.) |
| 7.2.3.Pfizer Inc. (U.S.) |
| 7.2.4.MorphoSys AG (Germany) |
| 7.2.5.Amgen Inc. (U.S.) |
| 7.2.6.Johnson & Johnson Services, Inc. (U.S.) |
| 7.2.7.Kite Pharma (U.S.) |
| 8. Research Methodology |
| 9. Appendix and Abbreviations |
- Gilead Sciences, Inc. (U.S.)
- CTI BioPharma (U.S.)
- Pfizer Inc. (U.S.)
- MorphoSys AG (Germany)
- Amgen Inc. (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Kite Pharma (U.S.)